Terevalefim

Terevalefim

SCHEMBL7079437

C(=Cc1cccs1)c1ccn[nH]1.CCOC(=O)c1cc(C)nn1C(=O)c1ccc(Cl)cc1.O=C(c1ccc(Cl)cc1)n1ccc(-c2cc(-c3ccccc3)no2)n1

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MET

The experimentally established mechanism targets of Terevalefim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.33
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RAB9A P51151 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
TP53 P04637 2/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
POLB P06746 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
SIRT3 Q9NTG7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terevalefim SCHEMBL7169262 0.86 ELANE (0.42) ELANEALDH1A1KMT2AMAPTSMN1; SMN2
Terevalefim SCHEMBL7169259 0.86 ELANE (0.42) ELANEALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL1224671 0.72 RAB9A (0.54) ALDH1A1KMT2AMAPTSMN1; SMN2RAB9A
SCHEMBL6348254 0.68 ENPP3 (0.62) ELANEALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL1225252 0.61 KMT2A (0.45) ELANEALDH1A1KMT2AMAPTRAB9A
SCHEMBL1225255 0.61 KMT2A (0.45) ELANEALDH1A1KMT2AMAPTRAB9A
SCHEMBL1224414 0.60 RAB9A (0.54) ELANEALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL1505308 0.60 NPC1 (0.53) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
Terevalefim SCHEMBL1225336 0.58 KMT2A (0.49) ALDH1A1KMT2AMAPTSMN1; SMN2RAB9A
Terevalefim SCHEMBL1225335 0.58 KMT2A (0.49) ALDH1A1KMT2AMAPTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589997-B2 1-Phenylprop-2-en-1-one derivatives as wound healing, anticarcinogenic, antiarthritic, antitumor, antiproliferative, antiinflammatory or antimetastasis agents NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM 2003-07-08 US disclosed
US-20030045559-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045559-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET ELANE 1810/4885ALDH1A1 510/4885KMT2A 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.